-
2025-521314-25-00
5
2026-03-19
NPM1-m and KMT2A-r Acute Myeloid Leukemia
-
2025-520467-40-00
9
2026-03-16
High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in
-
2024-513911-28-00
10
2026-03-04
Acute Ischemic Stroke
-
2025-522170-36-00
5
2026-02-03
Diabetes Mellitus, Type 1
-
2025-522767-15-00
5
2026-01-27
Acute Myeloid Leukemia
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2024-516253-49-01
4
2025-12-12
advanced/metastatic HER2-positive breast carcinoma
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2025-521707-48-00
1
2025-11-26
KRAS Altered Advanced or Metastatic Solid Tumors
-
2025-520623-24-00
7
2025-11-19
MTAP-deleted Solid Tumors
-
2025-521315-39-00
1
2025-11-05
Axial spondyloarthritis
-
2024-516188-10-00
6
2025-10-07
Intracerebral haemorrhage
-
2023-508056-19-00
5
2025-10-02
HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2023-508057-19-00
5
2025-09-23
Advanced HER2-expressing Biliary Tract Cancer
-
2022-501867-42-01
9
2025-09-08
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu
-
2024-520107-12-00
5
2025-09-03
Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
-
2022-501866-22-00
9
2025-08-26
Acute Lymphoblastic Leukemia, in Relapse
Lymphoblastic Lymphoma (Precu
-
2024-518589-29-00
5
2025-08-21
Bronchiectasis
-
2024-512753-24-00
5
2025-08-05
Acute Myeloid Leukemia (AML)
-
2025-520557-36-00
1
2025-07-24
Advanced Solid Tumors
-
2024-516616-24-00
5
2025-07-23
Acromegaly
-
2025-521305-40-00
1
2025-07-22
Participants with Advanced Solid Tumors